ProBioGen is an internationally operating, privately held Contract Development & Manufacturing Organization (CDMO), focusing on Cell Line Engineering, Process Development and GMP Manufacturing of Biopharmaceuticals (Therapeutic Proteins and Viral Vaccines). More than 20 years of experience in mammalian cell culture, along with innovative scientific excellence and a strong intellectual property base make ProBioGen an established CDMO. The company covers the entire drug development value chain, including regulatory support for IND-filing. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
Besides its State-of-the Art Services, based on its established CHO Platform, ProBioGen develops innovative technologies, such as
- GlymaxX, a novel and simple, yet efficient Glyco-Engineering Technology to boost the ADCC activity of antibodies by minimizing their Fucose content, which, notably, can also be applied to existing antibody-producer cell lines
- AGE1® producer cell lines (Human, Duck, etc.) for safe and cost-efficient production of highly active glycoproteins and virus-based vaccines, as potent alternatives to existing platforms
- Unique Human Artificial Lymph Node technology to analyze drug & vaccine effects on the immune system in vitro (e.g. to identify potential adverse effects), as part of our broad portfolio of qualified cell-based assays.